Biologic effects of various doses of ethinyl estradiol in postmenopausal women. 1982

F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd

To determine which dosage of estrogen might provide physiologic replacement while minimizing adverse effects, 20 postmenopausal women were studied before and after oral administration of ethinyl estradiol. Twenty premenopausal women studied in the early and late follicular phases of the menstrual cycle were presumed to reflect normal physiologic function. Variable responses of the different biochemical and biologic markers to the actions of ethinyl estradiol were observed. Liver protein synthesis was the most sensitive measure of the action of ethinyl estradiol. In comparing the relative potencies of ethinyl estradiol with previously reported results observed with the usage of conjugated equine estrogens, the actions of 10 micrograms ethinyl estradiol were approximately equivalent to the biologic effects of 1.25 mg conjugated estrogens. The results suggest that ethinyl estradiol is far more potent than previously believed and that the daily administration of 10 micrograms, a dose lower than currently available commercial preparations, may be adequate for relief of symptoms of vaginal atrophy and may provide protection from the occurrence of osteoporotic fractures.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D004966 Estrogens, Conjugated (USP) A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate. Conjugated Equine Estrogen,Conjugated Estrogen,Estrogenic Substances, Conjugated,Progen,Carentil,Climarest,Climopax,Congest,Conjugated Equine Estrogens,Conjugated Estrogens,Dagynil,Estro-Feminal,Estrogenic Hormones, Conjugated,Estrogens, Conjugated,Femavit,Oestro-Feminal,Oestrofeminal,Prelestrin,Premarin,Presomen,Progens,Transannon,Conjugated Estrogenic Hormones,Conjugated Estrogenic Substances,Equine Estrogen, Conjugated,Equine Estrogens, Conjugated,Estro Feminal,Estrogen, Conjugated,Estrogen, Conjugated Equine,Oestro Feminal
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females
D005498 Follicular Phase The period of the MENSTRUAL CYCLE representing follicular growth, increase in ovarian estrogen (ESTROGENS) production, and epithelial proliferation of the ENDOMETRIUM. Follicular phase begins with the onset of MENSTRUATION and ends with OVULATION. Menstrual Cycle, Follicular Phase,Menstrual Cycle, Proliferative Phase,Menstrual Proliferative Phase,Preovulatory Phase,Phase, Follicular,Phase, Menstrual Proliferative,Phase, Preovulatory,Proliferative Phase, Menstrual
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014176 Protein Biosynthesis The biosynthesis of PEPTIDES and PROTEINS on RIBOSOMES, directed by MESSENGER RNA, via TRANSFER RNA that is charged with standard proteinogenic AMINO ACIDS. Genetic Translation,Peptide Biosynthesis, Ribosomal,Protein Translation,Translation, Genetic,Protein Biosynthesis, Ribosomal,Protein Synthesis, Ribosomal,Ribosomal Peptide Biosynthesis,mRNA Translation,Biosynthesis, Protein,Biosynthesis, Ribosomal Peptide,Biosynthesis, Ribosomal Protein,Genetic Translations,Ribosomal Protein Biosynthesis,Ribosomal Protein Synthesis,Synthesis, Ribosomal Protein,Translation, Protein,Translation, mRNA,mRNA Translations

Related Publications

F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
January 2001, Clinical and experimental obstetrics & gynecology,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
September 1997, Zhonghua fu chan ke za zhi,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
May 1996, Geburtshilfe und Frauenheilkunde,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
March 1968, Nordisk medicin,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
June 1986, The New England journal of medicine,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
July 2007, International journal of clinical pharmacology and therapeutics,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
September 1980, The Journal of clinical endocrinology and metabolism,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
January 1994, Circulation,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
January 1981, Cancer treatment reports,
F P Mandel, and F L Geola, and J K Lu, and P Eggena, and M P Sambhi, and J M Hershman, and H L Judd
June 1992, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!